Sage Therapeutics
Market Cap
US$4.5b
Last Updated
2021/03/07 00:30 UTC
Data Sources
Company Financials +
Executive Summary
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 19.1% per year for the next 3 years
Snowflake Analysis
Flawless balance sheet and undervalued.
Share Price & News
How has Sage Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SAGE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SAGE's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
-9.4%
SAGE
-4.3%
US Biotechs
-0.4%
US Market
1 Year Return
60.1%
SAGE
24.2%
US Biotechs
36.2%
US Market
Return vs Industry: SAGE exceeded the US Biotechs industry which returned 24.2% over the past year.
Return vs Market: SAGE exceeded the US Market which returned 36.2% over the past year.
Shareholder returns
| SAGE | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.4% | -4.3% | -0.4% |
| 30 Day | -2.4% | -10.3% | -2.3% |
| 90 Day | 7.3% | -0.8% | 5.0% |
| 1 Year | 60.1%60.1% | 26.1%24.2% | 39.1%36.2% |
| 3 Year | -56.7%-56.7% | 12.0%6.3% | 48.4%39.0% |
| 5 Year | 123.3%123.3% | 51.3%39.9% | 116.6%92.4% |
Long-Term Price Volatility Vs. Market
How volatile is Sage Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade2 months ago | Simply Wall St
Need To Know: Analysts Are Much More Bullish On Sage Therapeutics, Inc. (NASDAQ:SAGE)3 months ago | Simply Wall St
Analysts Just Made A Major Revision To Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue ForecastsValuation
Is Sage Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SAGE ($76.98) is trading below our estimate of fair value ($436.71)
Significantly Below Fair Value: SAGE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SAGE is good value based on its PE Ratio (6.6x) compared to the US Biotechs industry average (21.3x).
PE vs Market: SAGE is good value based on its PE Ratio (6.6x) compared to the US market (21.5x).
Price to Earnings Growth Ratio
PEG Ratio: SAGE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: SAGE is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (3.9x).
Next Steps
Future Growth
How is Sage Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
-19.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SAGE's earnings are forecast to decline over the next 3 years (-19.1% per year).
Earnings vs Market: SAGE's earnings are forecast to decline over the next 3 years (-19.1% per year).
High Growth Earnings: SAGE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SAGE's revenue is expected to decline over the next 3 years (-15.2% per year).
High Growth Revenue: SAGE's revenue is forecast to decline over the next 3 years (-15.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SAGE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Sage Therapeutics performed over the past 5 years?
-17.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SAGE has high quality earnings.
Growing Profit Margin: SAGE became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: SAGE has become profitable over the past 5 years, growing earnings by -17.8% per year.
Accelerating Growth: SAGE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SAGE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: SAGE's Return on Equity (29.2%) is considered high.
Next Steps
Financial Health
How is Sage Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SAGE's short term assets ($2.1B) exceed its short term liabilities ($67.2M).
Long Term Liabilities: SAGE's short term assets ($2.1B) exceed its long term liabilities ($19.7M).
Debt to Equity History and Analysis
Debt Level: SAGE is debt free.
Reducing Debt: SAGE has not had any debt for past 5 years.
Debt Coverage: SAGE has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SAGE has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Sage Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SAGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SAGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SAGE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SAGE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SAGE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.5yrs
Average management tenure
CEO
Barry Greene (57 yo)
0.25
Tenure
Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. He is a Director at BCLS Acquisition Corp. He ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Treasurer | 8yrs | US$3.93m | 0.061% $ 2.7m | |
| Chief Operating Officer | 0.83yr | US$4.95m | 0.0036% $ 161.8k | |
| Senior VP | 5.5yrs | US$3.95m | 0.0030% $ 135.3k | |
| Chief Innovation Officer | 7.58yrs | US$9.90m | 0.096% $ 4.3m | |
| Chief Medical Officer | 7.67yrs | US$3.97m | 0.014% $ 638.2k | |
| President | 0.25yr | no data | no data | |
| Senior Vice President of Technical Operations | 5.5yrs | no data | no data | |
| Chief Scientific Officer | 9.33yrs | US$3.67m | 0.23% $ 10.5m | |
| Vice President of Investor Relations | 1.75yrs | no data | no data | |
| Senior Vice President of People & Organizational Strategy | no data | no data | no data | |
| Senior Vice President of Global Regulatory Affairs & Policy | 3.92yrs | no data | no data | |
| Chief Research Officer | 5.5yrs | no data | no data |
5.5yrs
Average Tenure
57.5yo
Average Age
Experienced Management: SAGE's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Innovation Officer | 7.58yrs | US$9.90m | 0.096% $ 4.3m | |
| President | 0.25yr | no data | no data | |
| Independent Chairman | no data | US$1.16m | 0.52% $ 23.3m | |
| Independent Director | 6.5yrs | US$1.15m | 0% $ 0 | |
| Independent Director | 6.83yrs | US$1.14m | 0.0018% $ 79.5k | |
| Founder & Independent Director | 9.5yrs | US$1.13m | 0.68% $ 30.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.67yrs | US$1.13m | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.7yrs
Average Tenure
59.5yo
Average Age
Experienced Board: SAGE's board of directors are considered experienced (6.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
Top Shareholders
Company Information
Sage Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sage Therapeutics, Inc.
- Ticker: SAGE
- Exchange: NasdaqGM
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.494b
- Shares outstanding: 58.38m
- Website: https://www.sagerx.com
Number of Employees
Location
- Sage Therapeutics, Inc.
- 215 First Street
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SAGE | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jul 2014 |
| SG7 | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Jul 2014 |
| SG7 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2014 |
Biography
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intr...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/07 00:30 |
| End of Day Share Price | 2021/03/05 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.